Skip to content
Veracyte® Press Releases

Veracyte® Press Releases

Date Title and Summary Additional Formats
Toggle Summary New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 7, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with
View HTML
Toggle Summary Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Morgan Stanley 20 th Annual Global Healthcare
View HTML
Toggle Summary Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
New data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s
View HTML
Toggle Summary New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
Findings suggest Veracyte’s immuno-oncology biomarkers could help predict response to therapy, improve patient outcomes and guide immunotherapy clinical trials SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in
View HTML
Toggle Summary Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 11, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr , M.D., to its board of directors, effective immediately. “We are thrilled to welcome Eliav Barr to our board,” said Marc Stapley , Veracyte’s chief executive
View HTML
Toggle Summary Veracyte Announces Second Quarter 2022 Financial Results
Grew Total Revenue to $72.9 million , an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022 .
View HTML
Toggle Summary Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA
View HTML
Toggle Summary Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 14, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, August 2, 2022 . Company management will host a conference call and webcast to
View HTML
Toggle Summary New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 13, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data published today in PLOS ONE show
View HTML
Toggle Summary Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year. The annual award is based solely on employee feedback gathered through an
View HTML